Filing of Form 10-Q for Second Quarter
MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022
ROCKVILLE, MD, August 11, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.
A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.
MaxCyte Contacts:
US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400
|
US Media Relations Seismic Valerie Enes
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden
| +1 408-497-8568
+44 (0)20 7886 2500 |
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709 5700
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.